"1-phenyl-2-aminopropane"@en . "LD₅₀=180 mg/kg(subcutaneous injection in rat). The most common presenting symptoms seen are agitation, hallucinations, suicidal behaviour, and chest pain."@en . . "Amphetamine"@en . "approved"@en . . "Amphetamine is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Amphetamine is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Amphetamine is a homologue of phenethylamine."@en . . "Amphetamine forms easily absorbed molecules that are highly lipid soluble"@en . . . . "Humans and other mammals"@en . "15-40%"@en . . "\u03B1-methylphenethylamine"@en . . . . . . "10 hours"@en . "\u03B2-aminopropylbenzene"@en . "Amphetamine"@en . "alpha-Methylbenzeneethaneamine"@en . . "Guohong Wang, \"Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples.\" U.S. Patent US20020090661, issued July 11, 2002."@en . . . . "alpha-Methylphenylethylamine"@en . . . . . . . . . . . "Amphetamin"@en . . . . . . . . . "beta-Phenylisopropylamine"@en . . . "illicit"@en . . . "300-62-9"@en . . "For treatment of Attention Deficit Disorder with Hyperactivity (ADDH) and narcolepsy in children."@en . . "beta-Aminopropylbenzene"@en . . . "\u03B2-phenylisopropylamine"@en . . . . "Amphetamines stimulate the release of norepinephrine from central adrenergic receptors. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. The drug interacts with VMAT enzymes to enhance release of DA and 5-HT from vesicles. It may also directly cause the reversal of DAT and SERT."@en . . . . . . . . . . . . . . "\u03B1-methylbenzeneethaneamine"@en . "1-Phenylpropan-2-amin"@en . "beta-Phenylisopropylamin"@en . . . "Desoxynorephedrine"@en . . . "# Leith NJ, Kuczenski R: Chronic amphetamine: tolerance and reverse tolerance reflect different behavioral actions of the drug. Pharmacol Biochem Behav. 1981 Sep;15(3):399-404. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7291243 # Chaudhry IA, Turkanis SA, Karler R: Characteristics of \"reverse tolerance\" to amphetamine-induced locomotor stimulation in mice. Neuropharmacology. 1988 Aug;27(8):777-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3216957 # Sax KW, Strakowski SM: Behavioral sensitization in humans. J Addict Dis. 2001;20(3):55-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11681593 # Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15955613"@en . . "Amfetaminum"@en . . . . . . . . "Amfetamine"@en . . " "@en . . .